Travere Therapeutics, Inc. (TVTX)
| Market Cap | 4.86B+99.2% |
| Revenue (ttm) | n/a+77.1% |
| Net Income | n/a+74.3% |
| EPS | n/a+76.0% |
| Shares Out | 92.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 327,203.636 |
| Open | 53.39 |
| Previous Close | 53.44 |
| Day's Range | 51.63 - 53.39 |
| 52-Week Range | 22.59 - 68.73 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 70.60(+35.20%) |
| Earnings Date | n/a |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$TVTX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TVTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TVTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TVTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TVTX Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| FILSPARI | $141.08M | 87.43% |
| Tiopronin products | $20.27M | 12.57% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New TVTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TVTX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TVTX
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $195.82M |
| XBIState Street SPDR S&P Biotech ETF | $130.83M |
| IWMiShares Russell 2000 ETF | $125.24M |
| VXFVanguard Extended Market ETF | $71.61M |
| IWOiShares Russell 2000 Growth ETF | $44.67M |
| IBBiShares Biotechnology ETF | $36.94M |
Estimated from each fund’s disclosed top holdings × AUM
TVTX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from TVTX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score